{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T05:42:33Z","timestamp":1740980553651,"version":"3.38.0"},"reference-count":0,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2005,3,1]]},"abstract":"<jats:p> Our objective is to analyse patients diagnosed with late-stage HIV infection in the highly active antiretroviral therapy (HAART) area. A prospective, observational study of all patients with an initial CD4&lt;50 \u00d7 10<jats:sup>6<\/jats:sup>\/L was carried out. Epidemiological, clinical and HAART-associated data were analysed. Survival rates were estimated and pairs of survival curves were compared. The statistical program used was SPSS<jats:sup>\u00ae<\/jats:sup> (version 10). In all, 349 HIV-infected patients were diagnosed, 117 (33.5%) had late-stage disease, mean CD4 23.9 \u00d7 10<jats:sup>6<\/jats:sup>\/L and mean viral load (VL) 5.38 log<jats:sub>10<\/jats:sub>. In 98 men, mean age 39.5 years, percentage of AIDS cases at their first attendance was 83.8%. The median follow-up period was 28 months and 27 died. Pneumocystis carinii was the most frequent cause of AIDS (24.4%) and death (18.5%). Survival rates at 12, 24 and 36 months were 95.6%, 85.8% and 72.4%. HAART was started in 82.1%. VLs &lt;50 copies\/mL at one, two and three years of treatment were 55.2%, 55.7% and 58.0%. Resource utilization included 0.58 hospitalization\/patient\/year and 0.07 events\/patient\/year. HAART-related complications were as follows: 50% lipodystrophy, 9.7% hypertension, 22.2% hyperglycaemia, 26.4% hypercholesterolaemia, 31.9% hypertrygliceridaemia and 18.1% mixed hyperlipaemia. Over one-third of our patients have advanced HIV infection at diagnosis. However, the outcome is favourable, with a good immunovirological response and few new opportunistic events. HAART-related complications were frequent. <\/jats:p>","DOI":"10.1258\/0956462053420167","type":"journal-article","created":{"date-parts":[[2005,3,26]],"date-time":"2005-03-26T03:27:38Z","timestamp":1111807658000},"page":"252-255","source":"Crossref","is-referenced-by-count":5,"title":["Study of patients diagnosed with advanced HIV in the HAART era \u2013 OMEGA Cohort"],"prefix":"10.1177","volume":"16","author":[{"given":"J","family":"Santos","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Service, Hospital Virgen de la Victoria, Campus Teatinus s\/n, 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Palacios","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Service, Hospital Virgen de la Victoria, Campus Teatinus s\/n, 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Service, Hospital Virgen de la Victoria, Campus Teatinus s\/n, 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Service, Hospital Virgen de la Victoria, Campus Teatinus s\/n, 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"M\u00e1rquez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Service, Hospital Virgen de la Victoria, Campus Teatinus s\/n, 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,3,1]]},"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/0956462053420167","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/0956462053420167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T14:08:42Z","timestamp":1740924522000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1258\/0956462053420167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,1]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3,1]]}},"alternative-id":["10.1258\/0956462053420167"],"URL":"https:\/\/doi.org\/10.1258\/0956462053420167","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"type":"print","value":"0956-4624"},{"type":"electronic","value":"1758-1052"}],"subject":[],"published":{"date-parts":[[2005,3,1]]}}}